Literature DB >> 23348706

SIRT2 overexpression in hepatocellular carcinoma mediates epithelial to mesenchymal transition by protein kinase B/glycogen synthase kinase-3β/β-catenin signaling.

Juan Chen1, Anthony W H Chan, Ka-Fai To, Weixian Chen, Zhenzhen Zhang, Jihua Ren, Chunli Song, Yue-Sun Cheung, Paul B S Lai, Suk-Hang Cheng, Margaret H L Ng, Ailong Huang, Ben C B Ko.   

Abstract

UNLABELLED: Sirtuin 1 (SIRT1) has been implicated in telomere maintenance and the growth of hepatocellular carcinoma (HCC). Nevertheless, the role of other sirtuins in the pathogenesis of HCC remains elusive. We found that sirtuin 2 (SIRT2), another member of the sirtuin family, also contributes to cell motility and invasiveness of HCC. SIRT2 is up-regulated in HCC cell lines and in a subset of human HCC tissues (23/45). Up-regulations of SIRT2 in primary HCC tumors were significantly correlated with the presence of microscopic vascular invasion (P = 0.001), a more advanced tumor stage (P = 0.004), and shorter overall survival (P = 0.0499). Functional studies by short hairpin RNA-mediated suppression of SIRT2 expression in HCC cell lines revealed significant inhibition of motility and invasiveness. Depletion of SIRT2 also led to the regression of epithelial-mesenchymal transition (EMT) phenotypes, whereas the ectopic expression of SIRT2 in the immortalized hepatocyte cell line L02 promoted cell motility and invasiveness. Mechanistic studies revealed that SIRT2 regulates the deacetylation and activation of protein kinase B, which subsequently impinges on the glycogen synthase kinase-3β/β-catenin signaling pathway to regulate EMT.
CONCLUSIONS: Our findings have uncovered a novel role for SIRT2 in HCC metastasis, and provide a rationale to explore the use of sirtuin inhibitors in HCC therapy. (HEPATOLOGY 2013;).
Copyright © 2013 American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23348706     DOI: 10.1002/hep.26278

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  69 in total

1.  Serglycin (SRGN) overexpression predicts poor prognosis in hepatocellular carcinoma patients.

Authors:  Lu He; Xinke Zhou; Chen Qu; Yunqiang Tang; Qiong Zhang; Jian Hong
Journal:  Med Oncol       Date:  2013-08-31       Impact factor: 3.064

2.  Downregulation of ACSM3 promotes metastasis and predicts poor prognosis in hepatocellular carcinoma.

Authors:  Hao-Yu Ruan; Chen Yang; Xue-Mei Tao; Jia He; Ting Wang; Hui Wang; Cun Wang; Guang-Zhi Jin; Hao-Jie Jin; Wen-Xin Qin
Journal:  Am J Cancer Res       Date:  2017-03-01       Impact factor: 6.166

Review 3.  Causes of genome instability: the effect of low dose chemical exposures in modern society.

Authors:  Sabine A S Langie; Gudrun Koppen; Daniel Desaulniers; Fahd Al-Mulla; Rabeah Al-Temaimi; Amedeo Amedei; Amaya Azqueta; William H Bisson; Dustin G Brown; Gunnar Brunborg; Amelia K Charles; Tao Chen; Annamaria Colacci; Firouz Darroudi; Stefano Forte; Laetitia Gonzalez; Roslida A Hamid; Lisbeth E Knudsen; Luc Leyns; Adela Lopez de Cerain Salsamendi; Lorenzo Memeo; Chiara Mondello; Carmel Mothersill; Ann-Karin Olsen; Sofia Pavanello; Jayadev Raju; Emilio Rojas; Rabindra Roy; Elizabeth P Ryan; Patricia Ostrosky-Wegman; Hosni K Salem; A Ivana Scovassi; Neetu Singh; Monica Vaccari; Frederik J Van Schooten; Mahara Valverde; Jordan Woodrick; Luoping Zhang; Nik van Larebeke; Micheline Kirsch-Volders; Andrew R Collins
Journal:  Carcinogenesis       Date:  2015-06       Impact factor: 4.944

4.  Sirtuin 2 Isoform 1 Enhances Hepatitis B Virus RNA Transcription and DNA Synthesis through the AKT/GSK-3β/β-Catenin Signaling Pathway.

Authors:  Zahra Zahid Piracha; Hyeonjoong Kwon; Umar Saeed; Jumi Kim; Jaesung Jung; Yong-Joon Chwae; Sun Park; Ho-Joon Shin; Kyongmin Kim
Journal:  J Virol       Date:  2018-10-12       Impact factor: 5.103

5.  An Alternatively Spliced Sirtuin 2 Isoform 5 Inhibits Hepatitis B Virus Replication from cccDNA by Repressing Epigenetic Modifications Made by Histone Lysine Methyltransferases.

Authors:  Zahra Zahid Piracha; Umar Saeed; Jumi Kim; Hyeonjoong Kwon; Yong-Joon Chwae; Hyun Woong Lee; Jin Hong Lim; Sun Park; Ho-Joon Shin; Kyongmin Kim
Journal:  J Virol       Date:  2020-07-30       Impact factor: 5.103

6.  Sirtuin 3 inhibits hepatocellular carcinoma growth through the glycogen synthase kinase-3β/BCL2-associated X protein-dependent apoptotic pathway.

Authors:  C-L Song; H Tang; L-K Ran; B C B Ko; Z-Z Zhang; X Chen; J-H Ren; N-N Tao; W-Y Li; A-L Huang; J Chen
Journal:  Oncogene       Date:  2015-04-27       Impact factor: 9.867

7.  Histone deacetylase HDA6 enhances brassinosteroid signaling by inhibiting the BIN2 kinase.

Authors:  Yuhan Hao; Haijiao Wang; Shenglong Qiao; Linna Leng; Xuelu Wang
Journal:  Proc Natl Acad Sci U S A       Date:  2016-08-25       Impact factor: 11.205

8.  A SIRT2-Selective Inhibitor Promotes c-Myc Oncoprotein Degradation and Exhibits Broad Anticancer Activity.

Authors:  Hui Jing; Jing Hu; Bin He; Yashira L Negrón Abril; Jack Stupinski; Keren Weiser; Marisa Carbonaro; Ying-Ling Chiang; Teresa Southard; Paraskevi Giannakakou; Robert S Weiss; Hening Lin
Journal:  Cancer Cell       Date:  2016-03-14       Impact factor: 31.743

9.  Obesity-induced lysine acetylation increases cardiac fatty acid oxidation and impairs insulin signalling.

Authors:  Osama Abo Alrob; Sowndramalingam Sankaralingam; Cary Ma; Cory S Wagg; Natasha Fillmore; Jagdip S Jaswal; Michael N Sack; Richard Lehner; Mahesh P Gupta; Evangelos D Michelakis; Raj S Padwal; David E Johnstone; Arya M Sharma; Gary D Lopaschuk
Journal:  Cardiovasc Res       Date:  2014-06-25       Impact factor: 10.787

Review 10.  Sirtuin inhibitors as anticancer agents.

Authors:  Jing Hu; Hui Jing; Hening Lin
Journal:  Future Med Chem       Date:  2014-05       Impact factor: 3.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.